Group 1 - CeriBell, Inc. reported a quarterly loss of $0.37 per share, better than the Zacks Consensus Estimate of a loss of $0.43, and an improvement from a loss of $1.85 per share a year ago, resulting in an earnings surprise of +13.95% [1] - The company posted revenues of $22.59 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.65%, and showing an increase from $17.19 million in the same quarter last year [2] - CeriBell, Inc. has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times in the same period [2] Group 2 - The stock has underperformed, losing about 56.2% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $23.33 million, and for the current fiscal year, it is -$1.55 on revenues of $86.82 million [7] - The Zacks Industry Rank for Medical - Products is in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

CeriBell (NasdaqGS:CBLL) Q3 2025 Earnings Call November 04, 2025 04:30 PM ET Speaker1Good afternoon, and thank you all for participating in today's call. Joining me from Ceribell are Jane Chao, Co-founder and Chief Executive Officer, and Scott Blumberg, Chief Financial Officer. Earlier today, Ceribell issued a press release announcing financial results for the quarter ended September 30th, 2025. A copy of the press release is available on the investor relations section of the company's website. Before we be ...

Financial Performance - Total revenue for the three months ended September 30, 2025, was $22.6 million, a 31% increase from $17.2 million in the same period of 2024[141]. - Product revenue increased by $3.7 million (28%) for the three months and $12.6 million (35%) for the nine months ended September 30, 2025, compared to the same periods in 2024, driven by new customer additions and increased product utilization[142]. - Subscription revenue rose by $1.7 million (44%) for the three months and $4.8 million (43%) for the nine months ended September 30, 2025, primarily due to increased subscription adoption[143]. - Gross profit for the three months ended September 30, 2025, was $19.9 million, a 33% increase from $15.0 million in 2024, with a gross margin of 88%[146]. - Net loss for the three months ended September 30, 2025, was $13.5 million, a 29% increase from a net loss of $10.4 million in the same period of 2024[141]. Operating Expenses - Total operating expenses for the three months ended September 30, 2025, were $34.6 million, a 39% increase from $24.9 million in 2024, with significant increases in research and development (47%) and sales and marketing (48%) expenses[141]. - Research and development expenses are expected to increase as the company continues to improve its algorithm and expand indications beyond seizures[132]. - Sales and marketing expenses are projected to rise as the company increases its sales organization and market penetration in the U.S. and seeks international opportunities[134]. - General and administrative expenses are expected to grow as the company increases headcount and incurs additional costs associated with being a public company[136]. Cash Flow and Financing - Cash used in operating activities for the nine months ended September 30, 2025, was $30.0 million, compared to $25.1 million in 2024[155]. - Cash used in investing activities significantly increased to $144.2 million for the nine months ended September 30, 2025, from $1.1 million in 2024, primarily due to marketable securities purchases[159]. - As of September 30, 2025, the company had $168.5 million in cash and cash equivalents and marketable securities, along with $20.0 million in term loans[163]. - The company expects to continue incurring losses and significant cash expenditures as it scales operations and invests in research and development and marketing[162]. - The company entered into a VLSA with SVB and Horizon, providing a term loan commitment of $50.0 million, of which $20.0 million was drawn at closing[164]. - A Revolving Facility was established for a line of credit of up to $10.0 million, maturing on February 6, 2026[165]. - The company believes that expected cash generated from revenue transactions and existing cash will be sufficient to fund planned operating expenses for at least the next 12 months[166]. - Future capital needs will depend on factors such as market acceptance of products and costs associated with product development and sales growth[167]. Regulatory and Market Position - The company has received a CE Mark for the Ceribell System in Europe and plans to pursue additional regulatory clearances internationally[120]. - The Ceribell System is designed to improve the detection and management of seizures in acute care settings, addressing significant delays and economic burdens associated with conventional EEG systems[118]. - As of September 30, 2025, the Ceribell System has been adopted by over 600 active accounts and has been used to care for over 200,000 patients[118]. Accounting and Estimates - Management's estimates and judgments in financial statements are based on historical experience and known trends, which may differ from actual results[169]. - There have been no material changes to significant accounting policies during the nine months ended September 30, 2025[170]. - Recent accounting pronouncements applicable to financial statements are described in the Quarterly Report on Form 10-Q[171].

Ceribell Reports Third Quarter 2025 Financial Results SUNNYVALE, Calif., November 4, 2025 – CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 & Recent Highlights "We are encouraged by our third quarter performance, which reflects strong commercial execution and continued momentum in adoption ...

Core Insights - CeriBell, Inc. reported a strong third quarter performance with total revenue of $22.6 million, marking a 31% increase from $17.2 million in the same quarter of 2024, driven by commercial traction and account expansion [4][11] - The company aims to establish point-of-care EEG as a new standard for seizure management, targeting a $2 billion addressable market opportunity [3][4] - CeriBell raised its full-year revenue guidance for 2025 to a range of $87 million to $89 million, indicating a growth of approximately 33% to 36% compared to the previous year [8] Financial Performance - Product revenue for Q3 2025 was $17.0 million, a 28% increase from $13.3 million in Q3 2024, while subscription revenue reached $5.6 million, up 44% from $3.9 million [4][11] - Gross profit for the quarter was $19.9 million, with a gross margin of 88%, slightly up from 87% in Q3 2024 [5][11] - Operating expenses increased by 39% to $34.6 million, primarily due to investments in the commercial organization and increased headcount [6][11] Net Loss and Cash Position - The net loss for Q3 2025 was $13.5 million, or $0.37 per share, compared to a net loss of $10.4 million, or $1.85 per share, in Q3 2024 [7][11] - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $168.5 million [7][11] Market Position and Strategy - CeriBell's focus is on generating robust clinical evidence to support the adoption of its technology in acute care settings [3][4] - The company ended the quarter with 615 total active accounts, reflecting its growing market presence [11]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for CeriBell, Inc. (CBLL) due to higher revenues, with a focus on how actual results will compare to estimates impacting stock price [1][2]. Earnings Expectations - CeriBell, Inc. is expected to report a quarterly loss of $0.43 per share, reflecting a year-over-year change of +76.8% [3]. - Revenues are projected to be $21.79 million, which is an increase of 26.8% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 2.33% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for CeriBell, Inc. is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +6.10% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - CeriBell, Inc. currently holds a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, CeriBell, Inc. was expected to post a loss of $0.40 per share but delivered a loss of -$0.38, resulting in a surprise of +5.00% [13]. - Over the past four quarters, the company has surpassed consensus EPS estimates two times [14]. Industry Comparison - Owens & Minor (OMI), another player in the Zacks Medical - Products industry, is expected to report an EPS of $0.23, reflecting a year-over-year change of -45.2% [18]. - Revenues for Owens & Minor are expected to be $700.91 million, down 74.2% from the previous year [18].

Company Overview - CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions [3] - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute care settings [3] - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3] - The system is FDA 510(k) cleared for indicating suspected seizure activity and is currently used in intensive care units and emergency rooms across the U.S. [3] Financial Results Announcement - CeriBell will release its financial results for the third quarter of 2025 after the close of trading on November 4, 2025 [1] - A conference call to discuss the financial results will begin at 1:30 p.m. PT / 4:30 p.m. ET on the same day [1] Investor Relations - Investors can listen to the conference call by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using access code 9394689 [2] - A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website [2]

Core Insights - CeriBell, Inc. has appointed Erica Rogers to its Board of Directors, bringing over 30 years of experience in leading high-growth medical device companies [1][2] - The company aims to expand patient access to timely brain monitoring in acute care settings, leveraging Rogers' expertise in scaling healthcare companies [1][3] Company Overview - CeriBell is a medical technology company focused on transforming the diagnosis and management of serious neurological conditions [5] - The Ceribell System is a point-of-care EEG platform designed for rapid diagnosis and continuous monitoring of patients, currently utilized in over 550 hospitals across the U.S. [5][3] - The system is FDA-cleared for detecting suspected seizure activity and combines portable hardware with AI-powered algorithms [5] Leadership Experience - Erica Rogers previously served as CEO of Silk Road Medical, leading the company from a 25-person startup to a publicly traded entity with over 500 employees and revenue exceeding $175 million [2] - Rogers has held board positions in various healthcare companies, emphasizing innovation and culture [2] Strategic Goals - The appointment of Rogers is seen as pivotal for CeriBell's growth phase, aiming to establish the Ceribell System as the standard of care in brain monitoring [3] - The company is focused on broadening access to its EEG technology to improve patient outcomes in critical care [3]

Summary of CeriBell (CBLL) FY Conference Call - August 12, 2025 Company Overview - **Company**: CeriBell (CBLL) - **Industry**: Medical Devices, specifically in neural monitoring and EEG technology - **Key Product**: Clarity, an AI-powered EEG hardware platform for seizure detection in acute care settings [2][3] Core Points and Arguments - **Market Opportunity**: The total addressable market (TAM) for seizure detection in the U.S. is over $2 billion, with a focus on ICU and emergency departments (ED) [3][4] - **Revenue Growth**: Last quarter's revenue was $21.2 million, with a year-over-year growth of 38% and a gross margin of 88% [3][4] - **Unmet Need**: Early and accurate seizure detection is critical, as one-third of neurological patients experience seizures, often without symptoms [4][5] - **Clinical Impact**: The device has shown to change physician decisions 40-50% of the time, significantly reducing ICU length of stay and patient transfers [11][12] - **Future Pipeline**: Plans to expand beyond seizure detection to include stroke, delirium, and potentially other neurological and psychiatric disorders [13][14] Financial Insights - **Growth Strategy**: The company is focused on account acquisition and same-store growth, with a current penetration of only 3% in the U.S. market [12][13] - **Investment in R&D**: Significant investments are being made in research and development to enhance product offerings and clinical evidence [57][58] Competitive Landscape - **Market Position**: CeriBell is the dominant player in the EEG market, having created the category and maintained leadership through superior product quality and clinical evidence [26][27] - **AI Advantage**: The company has accumulated data from over 200,000 patients, providing a strong foundation for its AI algorithms, which are continuously improved based on user feedback [29][30] Product Development - **New Features**: Plans to add features such as a camera for neonatal applications to improve EEG reading accuracy [32][34] - **Pediatric and Neonate Focus**: The company is targeting pediatric and neonatal populations, with significant opportunities in emergency departments [50][52] Sales and Marketing Strategy - **Sales Force Expansion**: The company has ramped up its sales force post-IPO, with a focus on training and productivity to drive account acquisition [36][39] - **Clinical Account Managers**: These managers are responsible for driving usage and educating hospital staff on the need for EEG monitoring [42][44] Barriers to Adoption - **Awareness and Approval Processes**: The main barriers to adoption include a lack of awareness and the lengthy hospital approval processes [54][55] Future Outlook - **Standard of Care**: The goal is to make EEG monitoring a standard vital sign in hospitals, supported by clinical evidence and partnerships [56][58] - **Cash Utilization**: The company plans to use its cash reserves to grow its commercial infrastructure, invest in R&D, and generate clinical evidence [57][58]

Core Insights - CeriBell reported Q2 2025 revenue of $21.2 million, a 38.5% increase from $15.3 million in Q2 2024, surpassing analyst expectations of $20.45 million [1][2] - The company experienced a net loss of $13.6 million, widening from $8.9 million in Q2 2024, despite improvements in gross margin to 88% [1][2][8] Financial Performance - Revenue (GAAP) for Q2 2025 was $21.2 million, up 38.5% year-over-year from $15.3 million in Q2 2024 [2] - Earnings per share (EPS, GAAP) were $(0.38), better than the expected $(0.40) and a significant improvement from $(1.61) in Q2 2024, reflecting a 76.4% year-over-year change [2] - Gross margin improved to 88%, up from 86% in Q2 2024, attributed to a higher proportion of subscription revenue [2][6] - Operating expenses increased by 55.6% year-over-year to $33.6 million, primarily driven by sales and marketing costs [2][7] - The net loss widened to $13.6 million, compared to $8.9 million in Q2 2024, although the loss per share showed improvement [2][8] Business Model and Strategy - CeriBell's business model relies on recurring revenue from disposable headbands and subscription fees for its Clarity platform, which provides AI-driven seizure analysis [4] - The company aims to expand its customer base across acute care hospitals and broaden clinical indications for its technology, supported by FDA regulatory clearance [4][12] - As of Q2 2025, CeriBell had 584 active accounts, an increase from 558 at the end of Q1 2025, although the pace of new signings has slowed [5] Product and Market Expansion - The Ceribell System combines rapid EEG hardware with AI algorithms for real-time seizure detection, allowing non-specialists to monitor patients [3][10] - Clarity, the AI platform, recently received FDA clearance for pediatric use, although significant revenue from this segment is not expected until 2025 [11] - CeriBell serves approximately 3% of the U.S. market for rapid EEG monitoring, indicating substantial growth potential [12] Outlook and Guidance - Management raised the revenue outlook for full year 2025 to $85 million to $88 million, reflecting confidence in sustained growth and account expansion [14] - Gross margin is expected to remain in the mid-80% range, with strategies in place to mitigate potential tariff impacts [14][15]